Zynerba Pharmaceuticals, Inc. Securities Litigation

If you purchased a significant amount of shares of Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), you have certain options. Investors should contact us.

 

Lawsuit Overview

Defendant:Zynerba Pharmaceuticals, Inc.
Date Filed:October 23rd, 2019
Sector:Health Care
Industry:Major Pharmaceuticals

According to the Complaint, Zynerba Pharmaceuticals, Inc. was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba operates as a clinical stage specialty pharmaceutical company. The Company focuses on developing pharmaceutically-produced transdermal CBD therapies for rare and near-rare neuropsychiatric disorders.

The Complaint alleges that Defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Zygel was proving unsafe and not well-tolerated in the BELIEVE 1 Trial; (2) the foregoing created a foreseeable, heightened risk that Zynerba would fail to secure the necessary regulatory approvals for commercializing Zygel for the treatment of DEE in children and adolescents; and (3) as a result, Zynerba's public statements were materially false and misleading at all relevant times.

Sign up for free to create a personalized portfolio with tracking and e-mail alerts for Zynerba Pharmaceuticals, Inc.

 
First Identified Complaint

Andy Velayos, et al. v. Zynerba Pharmaceuticals, Inc., et al.

Date Filed:October 23rd, 2019
Class Period Start:March 11th, 2019
Class Period End:September 17th, 2019
First Identified Complaint Filings
#Document TitleFiling Date